Brallobarbital: Difference between revisions
CSV import |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 26: | Line 26: | ||
{{stub}} | {{stub}} | ||
== Brallobarbital == | |||
<gallery> | |||
File:Brallobarbital.svg|Brallobarbital chemical structure | |||
File:Brallobarbital_ball-and-stick_animation.gif|Brallobarbital ball-and-stick model animation | |||
</gallery> | |||
Latest revision as of 19:11, 16 March 2025
Brallobarbital is a barbiturate developed in the 1920s. It has sedative and hypnotic properties, and was used for the treatment of insomnia.
History[edit]
Brallobarbital was first synthesized in the 1920s by the pharmaceutical company Hoffmann-La Roche. It was marketed under the brand name Vesparax, often in combination with other drugs such as secobarbital and amobarbital.
Pharmacology[edit]
As a barbiturate, brallobarbital acts as a central nervous system depressant, producing effects ranging from mild sedation to total anesthesia. It works by enhancing the action of the neurotransmitter GABA in the brain, which results in a decrease in nerve cell activity.
Medical uses[edit]
Brallobarbital was primarily used as a treatment for insomnia. However, due to its potential for abuse and the development of tolerance, it has largely been replaced by other, safer medications.
Side effects[edit]
Common side effects of brallobarbital include drowsiness, dizziness, and impaired coordination. More serious side effects can include respiratory depression, addiction, and in rare cases, death.
Legal status[edit]
In many countries, brallobarbital is a controlled substance due to its potential for abuse and addiction.


